trending Market Intelligence /marketintelligence/en/news-insights/trending/2g7x16w1-yn6nswzykhxeg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Innate Immunotherapeutics to buy cancer drug developer in all-stock deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Innate Immunotherapeutics to buy cancer drug developer in all-stock deal

Innate Immunotherapeutics Ltd signed a conditional agreement to acquire all shares of privately held Amplia Therapeutics Pty. Ltd. in exchange for new ordinary shares of Innate.

As part of the deal, Innate will acquire Melbourne-based Amplia's program on focal adhesion kinase, or FAK, a potential target in cancer therapy. Amplia has two FAK-targeting drug candidates, AMP886 and AMP945, which are in-licensed from Cancer Research Technology Ltd., a unit of Cancer Research UK.

Sydney-based Innate plans to refocus on cancer therapies after its multiple sclerosis drug candidate MIS416 failed in a phase 2b trial in October 2017. In the short term, the company will review opportunities for MIS416 and expects to advance at least one of the two Amplia drug candidates to phase 1 stage within a year.

Following the closing of the transaction, Amplia shareholders will hold 45% of Innate's total issued capital, and the Innate board will be composed of three Innate directors and three directors nominated by Amplia.

The deal is subject to certain conditions, including approval by Innate shareholders. The company will also seek shareholder approval for a 1-for-10 consolidation of its stock.

The transaction is expected to close April 30.

Focal adhesion kinase is a protein whose increased expression has been linked with cancer cell migration, proliferation, and survival.